Navigation Links
SanBio Announces The Completion Of Enrollment Of Its Clinical Trial Of Cell Therapy For Chronic Stroke Deficits
Date:9/4/2013

MOUNTAIN VIEW, Calif., Sept. 4, 2013 /PRNewswire/ -- SanBio Inc. today announced the successful completion of enrollment of patients in its Phase 1/2 clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, in patients suffering from chronic deficits resulting from previous stroke injuries. A total of 18 patients have been successfully administered SB623. The trial is being conducted at Stanford University and the University of Pittsburgh. No safety concerns have been attributed to the cell therapy product. For details regarding this clinical trial, please refer to www.clinicaltrials.gov/ct2/show/NCT01287936.

SB623 is derived from bone marrow and has shown safety and efficacy in rodent models of chronic stroke.  "Complete enrollment of this clinical trial is a major step in the development of SB623 for stroke patients. Planning for the next phase of testing is already underway." said Keita Mori, SanBio CEO.

SB623 is being delivered to the damaged region of the brains of patients who have suffered an ischemic stroke.  Product safety is the primary focus of the study but various measurements of efficacy are also being tested.

"Stroke is the major cause of disability in the United States. Regenerative medicine offers hope to those with otherwise permanent functional limitations. This trial represents an important advance in bringing restorative therapeutics for neurologic disorders into the clinical arena. Three measures of efficacy (NIHSS, ESS, Fugl-Meyer) all show a trend toward improvement.  We are looking forward to the next clinical trial," said Dr. Gary K. Steinberg, M.D., Ph.D., Bernard and Ronni Lacroute-William Randolph Hearst Professor of Neurosurgery and the Neurosciences, Director, Stanford Institute for Neuro-Innovation and Translational Neurosciences, Chairman, Department of Neurosurgery, Stanford University School of Medicine.

Dr. Steinberg will be presenting preliminary results from this clinical trial at the International Stroke Conference February 12-14 in San Diego, California.

"Completion of this study is an important milestone in development of cell therapy treatment for chronic stroke. The demonstration of safety and feasibility is encouraging and we look forward to further trials using these cells," said Dr. Lawrence R. Wechsler, M.D., Henry B. Higman Professor and Chair, Department of Neurology, University of Pittsburgh Medical School

"The SanBio trial was completed smoothly and will help to guide important research into stroke repair and regenerative medicine strategies. It is hoped that the next study can begin soon and advance patient care," said Dr. Douglas Kondziolka, MD, MSc ,FRCSC, FACS,Professor of Neurosurgery, Vice-Chair, Clinical Research (Neurosurgery), Professor of Radiation Oncology, Director, Center for Advanced Radiosurgery, NYU Langone Medical Center.

About SB623: SB623 is a proprietary allogeneic cell therapy product consisting of cells derived from bone marrow.  SB623 is administered adjacent to the area damaged by stroke and functions by producing proteins that aid the regenerative process.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.

For more information: www.san-bio.com


'/>"/>
SOURCE SanBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
2. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against NuVasive, Inc.
3. Hamilton Regional Laboratory Medicine Program Announces Decision to Acquire COPANs WASPLab, the Next Generation Full Laboratory Automation and Digital Bacteriology System
4. IVD Technology Magazine Announces the IVD Business Strategy Conference in San Diego
5. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
6. Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
7. Encision Announces Death of Chief Executive Officer Fred F. Perner
8. Sanomedics Announces Completion of Prime Time Medical Acquisition
9. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
10. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
11. Neurotrope, Inc., Announces Reverse Merger and Completion of $21.9 Million Private Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... National Pharmacy Services, LLC ("Maxor"), today announced that it has ... of Texas -based Maxor Specialty / IV ... both company,s clinical expertise and high-touch patient service models to ... About Maxor ... , , Established ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific Corporation ... agreement to acquire certain manufacturing assets and capabilities of ... NVC) advanced biological tissue business, as well as a ... $75 million in cash. The Neovasc advanced biological tissue ... the Boston Scientific Lotus™ Valve System. * Upon ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to ... which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping ... prolonging life 6 years in the last 3 decades,” says Dr. Valentine Fuster, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, Inc. ... the first company to offer robotic imaging to veterinary medicine is sponsoring the ... 941 for the American Association of Equine Practitioners 62nd Annual Convention from December ...
(Date:12/2/2016)... ... ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, has published ... Yisrayl says this generation, known as the Last Generation, started in 1934 A.Y. (After ... up exactly with Bible Prophecy – a protected way for those who will believe. ...
(Date:12/2/2016)... ... December 02, 2016 , ... On ... individuals and families from eight different sites throughout Miami-Dade and Broward counties. This ... volunteers worked very hard on Thanksgiving morning by putting together individual meals via ...
Breaking Medicine News(10 mins):